Loading organizations...
4baseCare is a Bengaluru, India-based biotechnology company that provides precision oncology solutions and advanced genomic testing to develop personalized cancer treatment plans. The organization analyzes tumor DNA to identify specific genetic mutations, utilizing proprietary bioinformatics and population-specific tumor gene panels tailored for Asian demographics. The company has secured over $41 million in total financing, highlighted by a $40 million Series B round in 2024 led by Yali Capital, with additional venture backing from the Infosys Innovation Fund and the Illumina Accelerator. 4baseCare delivers its genomic profiling services to healthcare providers and oncology centers, maintaining clinical and research partnerships with institutions such as Apollo Hospitals and Memorial Sloan Kettering. The enterprise recently expanded its international operations by establishing a CAP-accredited genomics laboratory in Dubai. 4baseCare was founded in 2018 by Hitesh Goswami and Kshitij Rishi.
4baseCare has raised $17.8M across 3 funding rounds.
4baseCare has raised $17.8M in total across 3 funding rounds.
4baseCare has raised $17.8M across 3 funding rounds. Most recently, it raised $9.8M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 27, 2026 | $9.8M Series B | Ashish Kacholia, Lashit Sanghvi | — | Announced |
| Aug 4, 2024 | $6M Series A | Mathew Cyriac | Akhil Aryan, Amit Lakhotia, Anjana Reddy, Gaurav Munjal, Harshil Mathur, Kunal Shah, Lalit Keshre, Mukesh Bansal, Natasha Malpani, Nitin Gupta, Ramakant Sharma, RAM Raheja, Sanjay Mandava, Sanket Shah, Shashank Kumar, Subho RAY, Tanmay Bhat, Varun DUA, Vidit Aatrey | Announced |
| Mar 1, 2021 | $2M Seed | First IN Ventures, Sherif Kottapurath | Merak Ventures, Season TWO Ventures, Manu Rikhye | Announced |
4baseCare has raised $17.8M in total across 3 funding rounds.
4baseCare's investors include Ashish Kacholia, Lashit Sanghvi, Mathew Cyriac, Akhil Aryan, Amit Lakhotia, Anjana Reddy, Gaurav Munjal, Harshil Mathur, Kunal Shah, Lalit Keshre, Mukesh bansal, Natasha Malpani.
4baseCare is a Bengaluru-based precision oncology company founded in 2018 that develops advanced genomic testing solutions and digital health tools to personalize cancer care, primarily in Asia and the Middle East.[1][2][4] It offers comprehensive genomic panels for somatic and germline mutation analysis via next-generation sequencing (NGS) from tissue or liquid biopsies, alongside the 4Care app for managing medical records and the OncoBuddy platform for patient support and community building.[1][2][6] Serving oncologists, cancer patients, and healthcare providers, 4baseCare addresses gaps in targeted therapy selection by enabling biomarker identification for optimal treatments, while building population-specific datasets like the Global Cancer Diversity Atlas (GCDA) to improve diagnostics and research.[2][4] The company has expanded rapidly with labs in Bangalore, Jammu, Kerala, Nepal, Manila (opened May 2025), and Dubai (CAP-accredited), demonstrating strong growth momentum as an Illumina Accelerator participant.[2][3][4]
4baseCare was co-founded in 2018 by Hitesh Goswami (CEO, with 12+ years in pharma drug discovery and genomics) and Kshitij Rishi (background in senior leadership at Deloitte and GE in strategy, operations, and marketing).[1][2] The idea emerged from a mission to revolutionize precision oncology in Asia by combining advanced genomics with digital health to personalize patient care and match patients to targeted therapies via biomarker profiling.[1][4] Early traction came from developing unique comprehensive genomic panels and tools like the Somatic Genomic Testing (SGT) kit, OncoBuddy for holistic patient support, and the 4Care app, positioning it as a pioneer in onco-tech.[1][2] Pivotal moments include selection as an Illumina Accelerator company and recent international lab expansions, including partnerships in Dubai with Innovate Life Sciences and in the Philippines with LINCs.[2][3]
4baseCare rides the precision medicine wave in oncology, where genomic sequencing personalizes treatments amid rising cancer incidence in Asia and underrepresented populations globally.[1][2][4] Timing is ideal as NGS costs drop, liquid biopsies advance, and demand grows for diverse datasets to counter Western-biased research, with GCDA filling critical gaps for population-specific insights.[2] Market forces like aging populations, expanding targeted therapies, and digital health adoption in emerging markets favor its model, influencing the ecosystem by accelerating research, enabling real-world evidence studies, and supporting oncologists in resource-limited settings.[5][6] As an Illumina-backed player expanding to the Middle East and Southeast Asia, it democratizes precision oncology, potentially reshaping cancer care standards in high-burden regions.[2][3]
4baseCare is poised for accelerated global scaling with new labs and GCDA driving data flywheels for AI-enhanced diagnostics and therapies.[2] Trends like multi-omic integration, AI in oncology, and regulatory pushes for personalized medicine will amplify its edge, especially in diverse markets.[1][6] Its influence may evolve from regional innovator to global leader in inclusive cancer genomics, potentially attracting partnerships or acquisitions amid booming healthtech investments—building on its foundation of giving patients the best shot at fighting cancer.[4]
